LAPTM4B-35是胶质母细胞瘤的新型预后因素
该研究用免疫组化检测77例胶质瘤(II级18例、III级16例、IV级43例)中LAPTM4B-35、pAkt、因子VIII和Ki-67的表达,发现LAPTM4B-35高表达与胶质母细胞瘤微血管密度高、pAkt激活及更差的无进展生存和总生存相关,多因素分析提示其为独立预后因素。
要点
- II级胶质瘤LAPTM4B-35表达评分低于III-IV级(p < 0.05),III级与IV级间差异无统计学意义。
- 43例胶质母细胞瘤中27例(62.8%)LAPTM4B-35高表达,与高肿瘤微血管密度和pAkt激活相关。
- 高表达组中位PFS 5.13个月 vs 低表达组12.0个月,中位OS 12.5个月 vs 29.6个月(均p < 0.0001)。
核心结论
- LAPTM4B-35与胶质母细胞瘤的肿瘤增殖、肿瘤血管生成及不良结局密切相关,可能作为新型预后标志物并可能在改善胶质母细胞瘤治疗中发挥作用。
研究设计与样本
- 对77例胶质瘤病例(II级18例、III级16例、IV级43例)进行免疫组化检测LAPTM4B-35、pAkt、因子VIII和Ki-67的表达,并分析其与预后的关系。
主要发现
- II级胶质瘤LAPTM4B-35表达评分低于III-IV级胶质瘤(p < 0.05),III级与IV级胶质瘤之间差异无统计学意义。
- 43例胶质母细胞瘤患者中27例(62.8%)LAPTM4B-35高表达,高表达与高肿瘤微血管密度和pAkt激活相关。
- 胶质母细胞瘤高表达组中位PFS为5.13个月,较低表达组12.0个月显著缩短(p < 0.0001)。
- 胶质母细胞瘤高表达组中位OS为12.5个月,较低表达组29.6个月显著缩短(p < 0.0001)。
- 多因素分析提示LAPTM4B-35是胶质母细胞瘤患者PFS和OS的独立预后因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lysosome-associated protein transmembrane-4 beta (LAPTM4B)-35, a newly identified cancer-associated gene, is overexpressed in a wide variety of malignant tumors. However, studies of its expression and role in glioma have not yet been reported. This study aimed to investigate the expression and the role of LAPTM4B-35 in glioma and to assess its value as a prognostic factor. Seventy-seven glioma cases (Grade II in 18 patients, Grade III in 16 and Grade IV in 43) were immunohistochemically examined for LAPTM4B-35, pAkt, factor VIII and Ki-67 expressions. The LAPTM4B-35 expression score of Grade II gliomas was lower than those of Grade III-IV gliomas (p < 0.05), while the difference between Grade III and IV gliomas was not statistically significant. Of the 43 patients with glioblastoma (GBM), 27 (62.8%) had high LAPTM4B-35 expression, which was associated with high tumor micro-vessel density and pAkt activation. The median progression-free survival (PFS) of GBM patients with high LAPTM4B-35 expression was 5.13 months, significantly shorter than that of those with low LAPTM4B-35 expression (12.0 months, p < 0.0001). The median overall survival (OS) of GBM patients with high LAPTM4B-35 expression was 12.5 months, again significantly shorter than that of those with low LAPTM4B-35 expression (29.6 months, p < 0.0001). Multivariate analysis indicated LAPTM4B-35 to be an independent prognostic factor for PFS and OS of GBM patients. Our findings show LAPTM4B-35 to be strongly associated with tumor proliferation, tumor angiogenesis and poor outcomes of GBM patients, suggesting LAPTM4B-35 to potentially be applicable as a novel prognostic marker and even to possibly play a role in improving GBM treatment.
引用
- Dong X, Tamura K, Kobayashi D, et al. LAPTM4B-35 is a novel prognostic factor for glioblastoma. J Neurooncol. 2017. PMID: 28097442. doi:10.1007/s11060-017-2369-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。